A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Inclusion Criteria

• Inclusion Criteria. - Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer. - Recurrent, locally advanced, unresectable or metastatic breast cancer with disease progression following anti-estrogen therapy. - Prior treatment with at least 2 chemotherapy regimens: - At least 1 of these regimens must have been administered in the metastatic setting. - At least 1 of these regimens must have contained a taxane. - No more than 2 prior chemotherapy regimens in the metastatic setting. - Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group scale. - Have discontinued all previous therapies for cancer. - Have the presence of measureable disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1. Exclusion Criteria: - Have either a history of central nervous system (CNS) metastasis or evidence of CNS metastasis on the magnetic resonance image of brain obtained at baseline. - Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor. - Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug. - Have had major surgery within 14 days of the initial dose of study drug. - Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).